Valuation: BioNTech SE

Market Cap 19.98B 22.86B 18.47B 17.06B 32.13B 2,196B 32.71B 220B 86.41B 1,075B 85.87B 83.97B 3,702B P/E 2026 *
-18x
P/E 2027 * -17.3x
Enterprise Value 9.12B 10.44B 8.43B 7.79B 14.67B 1,003B 14.94B 101B 39.46B 491B 39.22B 38.35B 1,691B EV / Sales 2026 *
4.21x
EV / Sales 2027 * 4.79x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.49%
1 week-3.70%
Current month-3.21%
1 month-0.81%
3 months-9.46%
6 months-15.09%
Current year-5.39%
1 week 88.35
Extreme 88.35
94.62
1 month 88.35
Extreme 88.35
98.81
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/05Free

Executive/Senior Manager

22,655 0.0094%
12/05Free

Chief Operating Officer

22,655 0.0094%
12/05Free

Chief Financial Officer

33,982 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-3.70%-18.60%-15.99% 22.86B
-1.39%-6.15%+56.05%+71.53% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.57%-6.41%+6.02%+426.86% 23.87B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%+0.21%+39.31%-29.41% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
+0.04%-0.84%+26.28%+189.94% 14.02B
+1.04%-4.55%+73.46%+141.98% 12.38B
Average +2.48%+0.15%+56.42%+195.98% 25.16B
Weighted average by Cap. +1.83%+0.37%+53.85%+156.50%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 2B 1.85B 3.49B 238B 3.55B 23.9B 9.38B 117B 9.32B 9.11B 402B 2.23B 2.55B 2.06B 1.91B 3.59B 245B 3.65B 24.59B 9.65B 120B 9.59B 9.38B 413B
Net income -1.04B -1.19B -963M -890M -1.68B -115B -1.71B -11.49B -4.51B -56.09B -4.48B -4.38B -193B -1.16B -1.33B -1.08B -995M -1.87B -128B -1.91B -12.84B -5.04B -62.68B -5.01B -4.9B -216B
Net Debt -10.85B -12.42B -10.03B -9.27B -17.46B -1,193B -17.77B -120B -46.95B -584B -46.65B -45.62B -2,012B -9.29B -10.63B -8.58B -7.93B -14.93B -1,021B -15.21B -102B -40.16B -500B -39.91B -39.03B -1,721B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
16/07/26 USD 90.06 -0.38% 143,268
14/07/26 USD 90.40 +0.37% 923,470
13/07/26 USD 90.07 -1.55% 671,508
10/07/26 USD 91.49 -1.60% 551,755
09/07/26 USD 92.98 -0.59% 816,162
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
79.00EUR
Average target price
106.79EUR
Spread / Average Target
+35.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock